ATE526014T1 - Therapeutisches mittel gegen diabetische neuropathie - Google Patents

Therapeutisches mittel gegen diabetische neuropathie

Info

Publication number
ATE526014T1
ATE526014T1 AT07860442T AT07860442T ATE526014T1 AT E526014 T1 ATE526014 T1 AT E526014T1 AT 07860442 T AT07860442 T AT 07860442T AT 07860442 T AT07860442 T AT 07860442T AT E526014 T1 ATE526014 T1 AT E526014T1
Authority
AT
Austria
Prior art keywords
therapeutic agent
diabetic neuropathy
agent against
against diabetic
dimethylsulfonium
Prior art date
Application number
AT07860442T
Other languages
English (en)
Inventor
Mamoru Kiniwa
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE526014T1 publication Critical patent/ATE526014T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT07860442T 2006-12-26 2007-12-20 Therapeutisches mittel gegen diabetische neuropathie ATE526014T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006349987 2006-12-26
PCT/JP2007/075233 WO2008078826A1 (ja) 2006-12-26 2007-12-20 糖尿病性ニューロパチー治療剤

Publications (1)

Publication Number Publication Date
ATE526014T1 true ATE526014T1 (de) 2011-10-15

Family

ID=39562616

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07860442T ATE526014T1 (de) 2006-12-26 2007-12-20 Therapeutisches mittel gegen diabetische neuropathie

Country Status (9)

Country Link
US (1) US8247458B2 (de)
EP (1) EP2103305B1 (de)
JP (1) JP5023074B2 (de)
KR (1) KR101103157B1 (de)
CN (1) CN101563075B (de)
AT (1) ATE526014T1 (de)
AU (1) AU2007339153B2 (de)
CA (1) CA2674066C (de)
WO (1) WO2008078826A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6105977B2 (ja) * 2013-03-07 2017-03-29 国立大学法人九州大学 がん化学療法剤に起因する末梢神経障害予防剤及び／又は治療剤
EP4046633A1 (de) * 2018-06-27 2022-08-24 Algernon Pharmaceuticals Inc. Verwendung von repirinast in der prophylaxe oder behandlung von nierenfibrose oder nierenerkrankung

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4556737A (en) * 1983-03-11 1985-12-03 Taiho Pharmaceutical Company Limited Sulfonium compounds, processes for preparing the compounds and pharmacological composiitons containing the same
JPS59167564A (ja) 1983-03-11 1984-09-21 Taiho Yakuhin Kogyo Kk スルホニウム化合物
JP3634622B2 (ja) * 1998-05-01 2005-03-30 大鵬薬品工業株式会社 腎透析に伴うそう痒の治療剤
CA2317530C (en) * 1998-11-05 2004-04-27 Taiho Pharmaceutical Co., Ltd. Dysuria remedies
JP3885135B2 (ja) 2000-10-10 2007-02-21 幸彦 松田 Ｃ型又は非ｂ非ｃ型肝炎ウイルスによる肝機能異常の改善剤
US7138140B2 (en) * 2001-04-16 2006-11-21 Taiho Pharmaceutical Co., Ltd. Suplatast tosilate crystals
US20040087558A1 (en) * 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
US20050203142A1 (en) * 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
WO2004058709A1 (en) * 2002-12-23 2004-07-15 Millennium Pharmaceuticals, Inc. Ccr8 inhibitors
JP4370117B2 (ja) * 2003-03-28 2009-11-25 博夫 中山 化学物質過敏症治療薬
ITMI20031467A1 (it) * 2003-07-18 2005-01-19 Acraf Farmaco attivo nel dolore neuropatico
JP2005097220A (ja) * 2003-09-26 2005-04-14 Taiho Yakuhin Kogyo Kk 後腹膜線維症治療剤
US20070161696A1 (en) * 2004-04-23 2007-07-12 Zeldis Jerome B Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
JP4794148B2 (ja) * 2004-09-10 2011-10-19 大鵬薬品工業株式会社 ネフローゼ症候群治療剤
JP4498101B2 (ja) * 2004-11-04 2010-07-07 大鵬薬品工業株式会社 頭痛の予防及び／または治療剤
JP4676770B2 (ja) * 2005-01-21 2011-04-27 大鵬薬品工業株式会社 扁平苔癬の予防剤及び／又は治療剤

Also Published As

Publication number Publication date
AU2007339153A1 (en) 2008-07-03
CA2674066C (en) 2012-01-24
WO2008078826A1 (ja) 2008-07-03
US20100041764A1 (en) 2010-02-18
US8247458B2 (en) 2012-08-21
CA2674066A1 (en) 2008-07-03
KR101103157B1 (ko) 2012-01-04
JP5023074B2 (ja) 2012-09-12
JPWO2008078826A1 (ja) 2010-04-30
EP2103305A4 (de) 2010-08-18
CN101563075B (zh) 2011-09-28
AU2007339153B2 (en) 2010-11-25
EP2103305A1 (de) 2009-09-23
EP2103305B1 (de) 2011-09-28
KR20090096640A (ko) 2009-09-11
CN101563075A (zh) 2009-10-21

Similar Documents

Publication Publication Date Title
CY1119488T1 (el) Παραγων για θεραπεια ή/και αποτροπη διαταραχης υπνου
CY1116688T1 (el) Τροποποιητες φαρμακοκινητικων ιδιοτητων θεραπευτικων ειδων
LTC1781298I2 (lt) Farmacinės kompozicijos, turinčios benzoksazino, skirtos respiracinių ligų gydymui
ATE549323T1 (de) Prophylaktisches und/oder therapeutisches mittel gegen hyperlipidemie
BRPI0609636A2 (pt) formulações farmacêuticas
NO20052914L (no) Terapeutiske forbindelser
EA200601837A1 (ru) Бензоксазины для лечения заболеваний дыхательных путей
NO20065535L (no) Behandling av respiratorisk sykdom
CY1109880T1 (el) ΑΝΤΑΓΩΝΙΣΤΗΣ CaSR
BRPI0414581C1 (pt) composto, composição farmacêutica compreendendo o referido composto e uso do referido composto
CY1112124T1 (el) Ενωσεις και μεθοδοι για τη θεραπεια δυσλιπιδαιμιας
UY28774A1 (es) Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes.
NO20064282L (no) Morfolinforbindelser
DE602005027540D1 (de) Feste formulierungen von ospemifen
JP2008506643A5 (ja) 糖尿病の治療用の血糖値低下活性成分として使用するためのホスホチロシン・ホスファターゼ１ｂ(ｐｔｐ１ｂ)阻害剤としてのジフェニルアミン置換サリチルチアゾール誘導体及び関連化合物
DK1861100T3 (da) 3,11B-cis-dihydrotetrabenazin til behandling af en profilerativ sygdom eller en inflammation
DK1932522T3 (da) Terapeutisk middel mod leversygdom indeholdende 2-amino-1,3-propandiolderivat som aktiv bestanddel
EA200800302A1 (ru) Применение производных и аналогов тиазола при лечении рака
EA200701181A1 (ru) Лекарственные средства, предназначенные для лечения или предупреждения фиброзных заболеваний
MXPA06011467A (es) Combinacion de sustancias activas que comprenden un carbinol combinado con al menos un farmaco antiinflamatorio no esteroideo (nsaid).
CY1111022T1 (el) Νεοι φαρμακευτικοι συνδυασμοι για τη θεραπεια νοσων των αναπνευστικων οδων
CY1110130T1 (el) Παραγωγα μορφολινης για χρηση ως αγωνιστες ντοπαμινης στην θεραπευτικη αγωγη σεξουαλικης δυσλειτουργιας i.α.
NO20052908D0 (no) Aromatic compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents.
CY1112433T1 (el) Συνθεση ζιμποτεντανης που περιεχει μαννιτολη και μικροκρυσταλλικη κυτταρινη
CY1112718T1 (el) Ν- (2-υδροξυαιθυλ) -ν-μεθυλ-4- (κινολιν-8-υλ (1- (θειαζολ-4-υλμεθυλ) πιπεριδιν- 4 -υλιδενο) μεθυλ) βενζαμιδιο, η μεθοδος παρασκευης του καθως και η χρηση του για τη θεραπευτικη αγωγη πονου, αγχους και καταθλιψης

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties